checkAd
    Startseite > Aktien > Veracyte > Nachrichten
    Veracyte Aktie
    20,340
     
    USD
    +5,33 %
    +1,030 USD
    Letzter Kurs 02:00:00 Nasdaq
    20,340
     
    USD
    2.300 STK
    Geldkurs 29.04.24
    20,360
     
    USD
    200 STK
    Briefkurs 29.04.24
    ISIN: US92337F1075 · WKN: A1W7EA · SYM: VCYT · USA

    Neueste Nachrichten

    Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
    22.04.24 · Business Wire (engl.) · Veracyte
    New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
    22.04.24 · Business Wire (engl.) · Veracyte
    Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
    16.04.24 · Business Wire (engl.) · Veracyte
    Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
    27.02.24 · Business Wire (engl.) · Veracyte
    Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
    22.02.24 · Business Wire (engl.) · Veracyte
    Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
    21.02.24 · Business Wire (engl.) · Veracyte
    Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
    08.02.24 · Business Wire (engl.) · Veracyte
    Veracyte Completes Acquisition of C2i Genomics
    06.02.24 · Business Wire (engl.) · Veracyte
    Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
    08.01.24 · Business Wire (engl.) · Veracyte
    Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
    12.12.23 · Business Wire (engl.) · Veracyte
    Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
    01.12.23 · Business Wire (engl.) · Veracyte
    Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
    29.11.23 · Business Wire (engl.) · Veracyte